miCAR19 T / Antion Biosci - LARVOL DELTA

Multiplex cell engineering of allogeneic anti‐CD19 CAR T‐cells with tuned silencing of HLA class I limits rejection by both CD8 T‐cells and NK cells (ESGCT 2023) - "We successfully generated miCAR19 T-cells with complete TCR silencing and with tuned silencing of HLA-I over a range of 80-95%...Remarkably, there was a direct correlation between the level of HLA-I silencing and increasing cytotoxicity by NK cells. To conclude, we demonstrate use of the miCAR technology platform to multiplex engineer a novel class of hypoimmunogenic and allogenic CAR19 T-cells, offering a balanced protection from both CD8 T-cell and NK cell mediated rejection."

CAR T-Cell Therapy • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CD19 • CD8

Tuned Silencing of HLA-I Expression in Allogeneic CAR T-Cells Strikes a Balance Between Immune Rejection by CD8 T-Cells and NK Cells (ASGCT 2024) - "While CAR functionality was maintained in recursive cytotoxic assays against tumor cells, our novel allogeneic miCAR19 T-cells were non-alloreactive and remained largely protected from both CD8 T-cell and NK cell mediated cytotoxicity when HLA-I was silenced within a range of 80-90%. We therefore demonstrate key benefits of our technology platform, which not only facilitates multiplex engineering of fully functional allogeneic CAR T-cells, but also the ability to optimally tune down expression of molecules for optimal therapeutic benefit."

CAR T-Cell Therapy • IO biomarker • Graft versus Host Disease • Immunology • Oncology • CD8